Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/EPHA2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EPHA2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EPHA2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EPHA2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EPHA2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EPHA2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EPHA2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009719310 | Cervix | CC | intrinsic apoptotic signaling pathway | 85/2311 | 288/18723 | 4.56e-15 | 6.46e-12 | 85 |
GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
GO:001905810 | Cervix | CC | viral life cycle | 87/2311 | 317/18723 | 2.20e-13 | 1.20e-10 | 87 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
GO:005212610 | Cervix | CC | movement in host environment | 52/2311 | 175/18723 | 7.03e-10 | 8.76e-08 | 52 |
GO:004440910 | Cervix | CC | entry into host | 47/2311 | 151/18723 | 8.45e-10 | 1.03e-07 | 47 |
GO:005170110 | Cervix | CC | biological process involved in interaction with host | 57/2311 | 203/18723 | 1.18e-09 | 1.41e-07 | 57 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
GO:004671810 | Cervix | CC | viral entry into host cell | 44/2311 | 144/18723 | 5.47e-09 | 5.03e-07 | 44 |
GO:004440310 | Cervix | CC | biological process involved in symbiotic interaction | 71/2311 | 290/18723 | 7.94e-09 | 6.98e-07 | 71 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EPHA2 | SNV | Missense_Mutation | novel | c.689G>A | p.Cys230Tyr | p.C230Y | P29317 | protein_coding | deleterious(0) | benign(0.336) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EPHA2 | SNV | Missense_Mutation | rs754656950 | c.1012N>A | p.Val338Met | p.V338M | P29317 | protein_coding | tolerated(0.13) | benign(0.056) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
EPHA2 | SNV | Missense_Mutation | | c.625G>A | p.Ala209Thr | p.A209T | P29317 | protein_coding | deleterious(0) | benign(0.142) | TCGA-BH-A0AV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
EPHA2 | SNV | Missense_Mutation | | c.2928N>G | p.Ile976Met | p.I976M | P29317 | protein_coding | deleterious_low_confidence(0.05) | probably_damaging(0.986) | TCGA-BH-A0B7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
EPHA2 | SNV | Missense_Mutation | novel | c.638N>T | p.Glu213Val | p.E213V | P29317 | protein_coding | deleterious(0) | benign(0.054) | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
EPHA2 | insertion | Nonsense_Mutation | novel | c.331_332insTTAAGGAATTGGAGGTTTAGT | p.Gly111delinsValLysGluLeuGluValTerCys | p.G111delinsVKELEV*C | P29317 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EPHA2 | insertion | Nonsense_Mutation | novel | c.690_691insTGATTTTCCACTGGGGCCTCTATAGATGACACAC | p.Val231Ter | p.V231* | P29317 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EPHA2 | insertion | Frame_Shift_Ins | novel | c.636_637insACATTTTTAGCTGT | p.Glu213ThrfsTer185 | p.E213Tfs*185 | P29317 | protein_coding | | | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
EPHA2 | deletion | Frame_Shift_Del | novel | c.2352delC | p.Ala785ProfsTer26 | p.A785Pfs*26 | P29317 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
EPHA2 | SNV | Missense_Mutation | | c.2581C>T | p.Arg861Cys | p.R861C | P29317 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | DASATINIB | DASATINIB | 20360610 |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | TOZASERTIB | TOZASERTIB | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | LITHOGLYCOCHOLATE | LITHOGLYCOCHOLATE | 23489211 |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | MLN-8054 | MLN-8054 | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | OSI-632 | OSI-632 | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565850 | | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | DS-8895 | | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | DASATINIB | DASATINIB | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | MEDI-547 | | |
1969 | EPHA2 | DRUGGABLE GENOME, CELL SURFACE, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | N/A | | |